Vigil Neuroscience Inc (VIGL)

02:03 AM

Vigil Neuroscience Faces Market Risks from Preferred Stock Issuance and Potential Share Dilution - TipRanks

02:03 AM

Mar 13, 2025

Vigil Neuroscience stock surges 10% on positive Alzheimer’s drug data By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 13, 2025

Stifel maintains Buy on Vigil Neuroscience, target at $11 By Investing.com - Investing.com South Africa

Mar 13, 2025

Mar 13, 2025

Vigil Neuroscience, Inc. SEC 10-K Report - TradingView

Mar 13, 2025

Mar 13, 2025

Vigil Neuroscience, Inc. Reports Positive Phase 1 Data for VG-3927 and Outlines Upcoming Milestones in Alzheimer’s Disease and ALSP Treatment Programs - Nasdaq

Mar 13, 2025

Mar 13, 2025

Vigil Neuroscience, Inc. Loss At -$23.83 Mln In Q4 - Nasdaq

Mar 13, 2025

Mar 13, 2025

Vigil Neuroscience Reports Fourth Quarter and Full Year - GlobeNewswire

Mar 13, 2025

Mar 13, 2025

Vigil's Alzheimer's Drug Shows 50% Brain Biomarker Reduction in Phase 1 Success - StockTitan

Mar 13, 2025

Mar 13, 2025

SPY ETF News, 3/13/2025 - The Globe and Mail

Mar 13, 2025

Mar 11, 2025

Vigil Neuroscience to Present at the Stifel 2025 Virtual CNS Forum - GlobeNewswire

Mar 11, 2025

Mar 06, 2025

Will Vigil Neuroscience (NASDAQ:VIGL) Spend Its Cash Wisely? - Yahoo Finance

Mar 06, 2025

Mar 05, 2025

Best Stock to Buy Right Now: Dutch Bros vs. Starbucks - The Globe and Mail

Mar 05, 2025

Mar 04, 2025

Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Drops By 43.6% - Defense World

Mar 04, 2025

Mar 01, 2025

Why Vigil Neuroscience, Inc. (VIGL) is Skyrocketing So Far in 2025 - Insider Monkey

Mar 01, 2025

Feb 20, 2025

SHAREHOLDER ALERT: Purcell & Lefkowitz LLP Announces Shareholder Investigation of Vigil Neuroscience, Inc. (NASDAQ: VIGL) - PR Newswire

Feb 20, 2025

Feb 17, 2025

What Did We Find About Insider Trading At Vigil Neuroscience Inc (NASDAQ: VIGL)? - Stocks Register

Feb 17, 2025

Feb 16, 2025

Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial - MSN

Feb 16, 2025

Feb 16, 2025

Short Interest in Vigil Neuroscience, Inc. (NASDAQ:VIGL) Increases By 145.8% - MarketBeat

Feb 16, 2025

Feb 14, 2025

abrdn plc Purchases 293,461 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL) - MarketBeat

Feb 14, 2025

Feb 09, 2025

VIGLVigil Neuroscience, Inc. Latest Stock News & Market Updates - StockTitan

Feb 09, 2025

Feb 06, 2025

VIGL Stock Update: Vigil Neuroscience Inc’s Banking’s Market Struggles and Potential Opportunities - The InvestChronicle

Feb 06, 2025

Feb 05, 2025

The Attractiveness of Investing In Vigil Neuroscience Inc (VIGL) is Growing - Knox Daily

Feb 05, 2025

Feb 05, 2025

Are Vigil Neuroscience Inc’shares a good deal? - US Post News

Feb 05, 2025

Jan 30, 2025

Vigil Neuroscience to Present at Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire

Jan 30, 2025

Jan 30, 2025

Neurodegenerative Disease Pioneer Vigil to Reveal Latest Developments at Major Biotech Conference - StockTitan

Jan 30, 2025

Jan 27, 2025

Vigil Neuroscience Reports Positive Data from Phase 1 Clinical Trial on Potential Alzheimer’s Treatment - Defense World

Jan 27, 2025

Jan 26, 2025

Vigil Neuroscience shares rise on positive Alzheimer's trial data - MSN

Jan 26, 2025

Jan 26, 2025

Guggenheim Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World

Jan 26, 2025

Jan 25, 2025

Vigil Neuroscience's (VIGL) Buy Rating Reiterated at Guggenheim - MarketBeat

Jan 25, 2025

Jan 25, 2025

HC Wainwright Reaffirms “Buy” Rating for Vigil Neuroscience (NASDAQ:VIGL) - Defense World

Jan 25, 2025

Jan 24, 2025

HC Wainwright Reiterates Buy Rating for Vigil Neuroscience (NASDAQ:VIGL) - MarketBeat

Jan 24, 2025

Jan 24, 2025

Vigil moves into Phase II with Alzheimer's pill - The Pharma Letter

Jan 24, 2025

Jan 24, 2025

Vigil Neuroscience gains after early-stage data for Alzheimer’s drug (update) - MSN

Jan 24, 2025

Jan 24, 2025

Vigil Neuroscience advances Alzheimer's drug to Phase 2 trial By Investing.com - Investing.com South Africa

Jan 24, 2025

Jan 23, 2025

Vigil Neuroscience: Now A 'Hold' Based On Two New Pipeline Developments - Seeking Alpha

Jan 23, 2025

Jan 23, 2025

Vigil Neuroscience's Alzheimer's Candidate Shows Encouraging Safety Profile, Plans To Start Mid-Stage Study In Q3 - AOL

Jan 23, 2025

Jan 23, 2025

Vigil Neuroscience stock up on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha

Jan 23, 2025

Jan 23, 2025

Vigil Neuroscience stock gains on Alzheimer’s data (VIGL:NASDAQ) - Seeking Alpha

Jan 23, 2025

Jan 23, 2025

Vigil Neuroscience Announces Positive Phase 1 Trial Results - TipRanks

Jan 23, 2025

Jan 23, 2025

Vigil Neuroscience shares rise on positive Alzheimer's trial data By Investing.com - Investing.com Australia

Jan 23, 2025

Jan 23, 2025

12 Health Care Stocks Moving In Thursday's Pre-Market Session - Benzinga

Jan 23, 2025

Jan 23, 2025

Vigil Neuroscience Reports Positive Data from its Phase 1 - GlobeNewswire

Jan 23, 2025

Jan 23, 2025

Vigil Neuroscience Reports Positive Data from its Phase 1 Clinical Trial Evaluating VG-3927 for - The Bakersfield Californian

Jan 23, 2025

Jan 23, 2025

Vigil's Alzheimer's Drug Shows Promising Phase 1 Results with 50% Brain Biomarker Reduction - StockTitan

Jan 23, 2025

Jan 22, 2025

Vigil Neuroscience, Inc. Reports Positive Data from its Phase 1 Clinical Trial Evaluating Vv-3927 for the Potential Treatment of Alzheimer's Disease - Marketscreener.com

Jan 22, 2025

Jan 21, 2025

Suncor Energy: AI-Powered Stock Analysis on Jefferies Valuation Update - The Globe and Mail

Jan 21, 2025

Jan 20, 2025

Glimpse Group Inc (NASDAQ: VRAR) Down -21.05% This Year: What To Expect Next - Stocks Register

Jan 20, 2025